Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.

Cell reports. Medicine·2023

Same author

Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against <i>Candida glabrata</i>.

Journal of fungi (Basel, Switzerland)·2022

Same author

<i>In Vitro</i> Synergy of Isavuconazole Combined With Colistin Against Common <i>Candida</i> Species.

Frontiers in cellular and infection microbiology·2022

Same author

In Vitro Activity of Amphotericin B in Combination with Colistin against Fungi Responsible for Invasive Infections.

Journal of fungi (Basel, Switzerland)·2022

Same author

Complete Genome Sequences of Two Nosocomiicoccus ampullae Strains and a Growth-Adapted Mutant.

Microbiology resource announcements·2021

Same author

Tuberculosis of the Ankle in a Non-immunocompromised Male: A Case Report and Review of the Literature.

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons·2020

Search research articles

Related Experiment Video

Updated: Feb 15, 2026

Preparing Irradiated and Marked Male Aedes aegypti Mosquitoes for Release in an Operational Sterile Insect Technique Program

Preparing Irradiated and Marked Male Aedes aegypti Mosquitoes for Release in an Operational Sterile Insect Technique Program

Published on: March 12, 2021

Vardenafil Bayer Yakuhin.

Frank Sommer¹, Udo Engelmann

¹Department of Urology, University Medical Center of Cologne, Germany. Frank.Sommer.urologie@web.de

Current Opinion in Investigational Drugs (London, England : 2000)

|July 2, 2002

Summary

This summary is machine-generated.

Bayer is developing vardenafil, a phosphodiesterase type 5 inhibitor, for erectile dysfunction. Regulatory filings and clinical trials were underway in multiple countries, with anticipated market launches and significant sales projections.

More Related Videos

Visualizing and Tracking Endogenous mRNAs in Live Drosophila melanogaster Egg Chambers

Visualizing and Tracking Endogenous mRNAs in Live Drosophila melanogaster Egg Chambers

Published on: June 4, 2019

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

Related Experiment Videos

Last Updated: Feb 15, 2026

Preparing Irradiated and Marked Male Aedes aegypti Mosquitoes for Release in an Operational Sterile Insect Technique Program

Preparing Irradiated and Marked Male Aedes aegypti Mosquitoes for Release in an Operational Sterile Insect Technique Program

Published on: March 12, 2021

Visualizing and Tracking Endogenous mRNAs in Live Drosophila melanogaster Egg Chambers

Visualizing and Tracking Endogenous mRNAs in Live Drosophila melanogaster Egg Chambers

Published on: June 4, 2019

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

Area of Science:

Pharmacology
Drug Development

Background:

Erectile dysfunction (ED) is a condition affecting millions of men worldwide.
Phosphodiesterase type 5 (PDE5) inhibitors have emerged as a leading treatment for ED.

Purpose of the Study:

To outline the development status of vardenafil, an orally active PDE5 inhibitor.
To track regulatory progress and market entry timelines for vardenafil.

Main Methods:

Review of regulatory filings (NDAs) in the US, Mexico, Canada, Japan, and South Africa.
Monitoring of Phase III clinical trial progress in Japan.
Analysis of partnership agreements and sales forecasts.

Main Results:

New Drug Applications (NDAs) filed in multiple countries, with expected FDA response in 2002.
Phase III trials completed in Japan, with a projected 2003 launch.
Worldwide co-promotion agreement signed between Bayer and GlaxoSmithKline.

Conclusions:

Vardenafil demonstrated significant progress in regulatory and clinical development for erectile dysfunction.
Market entry was anticipated in key regions, with substantial sales potential projected.